Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$138.69 USD

138.69
682,554

-2.24 (-1.59%)

Updated May 21, 2024 04:00 PM ET

After-Market: $138.62 -0.07 (-0.05%) 5:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (48 out of 248)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Veeva Systems' (VEEV) Vault EDC Witnesses Increasing Adoption

Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

Veeva's strong product demand and strategic deals raise optimism about the stock.

GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite

GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.

Are Investors Undervaluing DaVita (DVA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tandem Diabetes (TNDM) Gains From Innovation Amid Competition

Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.

Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment

Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.

Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics

Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.

Reasons to Hold Patterson Companies (PDCO) in Your Portfolio

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Here's Why You Should Hold McKesson (MCK) in Your Portfolio

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?

Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.

Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?

Walgreens (WBA) fiscal second-quarter performance is likely to benefit from strong growth in the United States and the International front

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford

GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.

DaVita HealthCare (DVA) Is Up 1.09% in One Week: What You Should Know

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

DaVita HealthCare (DVA) Is Up 1.09% in One Week: What You Should Know

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

UnitedHealth (UNH) Faces Investigation Following Cyberattack

A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.

Reasons to Add Stryker (SYK) Stock in Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Revvity's (RVTY) New Launch to Boost Research Productivity

Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Climb Further

Investors target stocks that have been on a bullish run lately. Stocks like HST, EAT, DVA and PPC that are seeing price strength have a high chance of carrying the momentum forward.

Here's Why You Should Retain National Vision (EYE) Stock Now

The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).